Xolair is a monoclonal antibody that targets IgE, the allergy antibody protein responsible for allergic sensitization.
Xolair was approved in the year 2003 for the reduction of asthma exacerbations in patients with persistent
moderate to severe asthma. It has proven to be highly effective in select patients in reducing exacerbations,
improving the quality of life, as well as improving lung function.
Our office is highly selective in screening and recommending patients for Xolair. Xolair is given by injection
either once or twice a month for an indefinite period. Our patients who benefit from Xolair have been able to not
only have less exacerbations and improved quality of life, but also to reduce their dose of corticosteroid
Screening for Xolair encompasses a positive blood test or skin test to a perennial allergen, such as dust mites,
cat, dog or cockroach and a serum IgE. It also encompasses a history of persistent asthma according to the
guidelines of the Expert Panel 3, part of the NHLBI which were released in August 2007.
All of our physicians are experienced with Xolair, as is our physician assistant, and can discuss at length
specific requirements for treatment as well as appropriate facts about the Xolair injection and potential reactions
to it. Please do not hesitate to inquire about Xolair or any other treatments for your allergic condition.